Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FASN | P49327 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276717 | 0.92 | FASN (0.55) | TSHRALDH1A1FASNPPARAEPHX2 | |
| SCHEMBL9935348 | 0.87 | PPARA (0.48) | PPARAEPHX2F7F3FAAH | |
| SCHEMBL3138791 | 0.87 | PPARA (0.48) | PPARAEPHX2F7F3FAAH | |
| SCHEMBL1310713 | 0.85 | PPARA (0.47) | PPARAEPHX2F7F3FAAH | |
| SCHEMBL3135640 | 0.81 | EPHX2 (0.53) | PPARAEPHX2F7F3FAAH | |
| SCHEMBL17361017 | 0.81 | EPHX2 (0.53) | PPARAEPHX2F7F3FAAH | |
| SCHEMBL11504115 | 0.79 | EPHX2 (0.56) | PPARAEPHX2F7F3FAAH | |
| SCHEMBL11504832 | 0.79 | EPHX2 (0.56) | PPARAEPHX2F7F3FAAH | |
| SCHEMBL1282735 | 0.79 | ALDH1A1 (0.45) | TSHRALDH1A1FASNPPARAEPHX2 | |
| SCHEMBL11377546 | 0.79 | EPHX2 (0.56) | PPARAEPHX2F7F3FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640237-B1 | LIPID MEMBRANE STRUCTURE FOR DELIVERY INTO SIRNA CELL | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20230132645-A1 | LIPID MEMBRANE STRUCTURE FOR DELIVERY INTO SIRNA CELL | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-05-04 | — | — | US | disclosed |
| US-11517528-B2 | Lipid membrane structure for delivery into siRNA cell | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-12-06 | — | — | US | disclosed |
| CN-110740985-B | Lipid membrane structures for intracellular delivery of siRNA | 国立大学法人北海道大学 | 2022-08-02 | — | — | CN | disclosed |
| US-20200129431-A1 | LIPID MEMBRANE STRUCTURE FOR DELIVERY INTO siRNA CELL | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3640237-A1 | LIPID MEMBRANE STRUCTURE FOR DELIVERY INTO SIRNA CELL | National University Corporation Hokkaido University (JP) | 2020-04-22 | — | — | EP | disclosed |
| CN-110740985-A | Lipid membrane structures for intracellular delivery of siRNA | 国立大学法人北海道大学 | 2020-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132645-A1 | LIPID MEMBRANE STRUCTURE FOR DELIVERY INTO SIRNA CELL | ABCB4, NPC1L1, LDLR | TSHR 1466/4885ALDH1A1 3276/4885FASN 371/4885 |
| US-20200129431-A1 | LIPID MEMBRANE STRUCTURE FOR DELIVERY INTO siRNA CELL | ABCB4, LDLR, NPC1 | TSHR 1248/4885ALDH1A1 3390/4885FASN 656/4885 |
| US-11517528-B2 | Lipid membrane structure for delivery into siRNA cell | ABCB4, LDLR, NPC1 | TSHR 1248/4885ALDH1A1 3390/4885FASN 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.